Pharmafile Logo

News and Press Releases

Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus Chemotherapy

Data from Cohort 1 of the phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy 21 October 2023 --...

Category: Clinical Trials
Posted: October 23, 2023

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

European Commission Approves ADCETRIS (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD  

· Approval Based on Updated Positive Overall Survival Results from the phase 3 ECHELON-1 Study for Stage III & IV Hodgkin Lymphoma  · First Significant Improvement in Overall Survival in Two Decades...

Category: Pharmaceutical
Posted: October 23, 2023

Takeda Pharmaceutical Company
61 Aldwych, London, WC2B 4AE, UK

MSD’s WELIREG▼(belzutifan) made available for the treatment of eligible adults with von Hippel-Lindau (VHL) disease in Scotland

Scotland is the first European country to accept belzutifan as a treatment for adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL-associated renal cell carcinoma (RCC), central...

Category: Pharmaceutical
Posted: October 9, 2023

Merck
IECustomerrelations@merckgroup.com
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France

Broken String Biosciences strengthens senior leadership team to accelerate product development and commercialisation

Appointment of Vincent Smith PhD, as chief technology officer and Jessica Rich as VP of Business Development Follows Broken String’s successful $15m Series A fundraising round in September 2023 Will...

Category: Biotechnology
Posted: October 4, 2023

Broken String Biosciences
info@brokenstringbio.com
Unit AB3-04, Level 3 BioData Innovation Centre Wellcome Genome Campus Hinxton Cambridge, CB10 1DR

Broken String Biosciences Closes $15m Series A Funding Round

Funds to support further development and commercialisation of the company’s INDUCE-seq DNA break mapping technology Platform technology provides in situ off-target measurement in clinically relevant cells to accelerate the progression...

Category: Biotechnology
Posted: September 18, 2023

Broken String Biosciences
info@brokenstringbio.com
Unit AB3-04, Level 3 BioData Innovation Centre Wellcome Genome Campus Hinxton Cambridge, CB10 1DR